
|Articles|October 6, 2006
ESMO: Radiation Plus Hormone Therapy Is Prostate Cancer Plus
Author(s)Rabiya Tuma, Ph.D.
ISTANBUL, Turkey -- Progression-free survival is prolonged by 10% in men with locally advanced prostate cancer who receive both radiation and hormone therapy, according to a large meta-analysis.
Advertisement
ISTANBUL, Turkey, Oct. 6 -- Progression-free survival is prolonged by 10% in men with locally-advanced prostate cancer who receive both radiation and hormone therapy, Italian researchers reported here.
In a meta-analysis of 4,373 patients who had participated in seven randomized controlled phase III trials, there was a relative risk of relapse of 0.74 (95% confidence interval, 0.70, 0.78, P
Advertisement
Related Content
Advertisement


AD109 Reduces OSA Severity in Phase 3 Trial of CPAP-Intolerant Adults
Published: | Updated:



Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Clears Wave Neuroscience MeRT System for PTSD
2
AD109 Reduces OSA Severity in Phase 3 Trial of CPAP-Intolerant Adults
3
Zasocitinib Tops Deucravacitinib for Skin Clearance in Phase 3 Psoriasis Trial
4
Women With Moderate-to-Severe OSA Report Greater Symptom Burden Than Men
5





































































































































































